IBRX vs CORT
Side-by-side comparison of price performance, valuation, growth, profitability, analyst targets and technical trend.
IBRX · ImmunityBio$6.02 ▼ 8.37%
CORT · Corcept Therapeutics$63.62 ▼ 2.09%
One year, rebased to 100
Each line starts at 100 so growth is directly comparable
- IBRX +180.0%
- CORT -18.1%
Head to head
| Metric | IBRX | CORT |
|---|---|---|
| Price | $6.02 | $63.62 |
| Change today | ▼ 8.37% | ▼ 2.09% |
| Market cap | $6.40B | $6.96B |
| Return, 3 months | -20.6% | -48.4% |
| Return, year to date | +204.0% | +82.8% |
| Return, 1 year | +189.4% | -17.7% |
| P/E (TTM) | – | 47.8 |
| P/B | -5.6 | 8.4 |
| P/E percentile vs own 5y | 28th | 69th |
| Dividend yield | – | – |
| Revenue growth (YoY, latest qtr) | +52.3% | +64.0% |
| Net profit growth (YoY) | -174.3% | +544.6% |
| Gross margin | 98.8% | 98.5% |
| Operating margin | -150.2% | 11.5% |
| Net margin | -607.8% | 16.5% |
| Return on equity | – | 21.7% |
| Analyst target vs. price | +136.7% | +161.4% |
| Analyst buy share | 100% | 100% |
| RSI (14) | 36 | 21 |
| 30-day volatility | 101.0% | 78.5% |
| Max drawdown, 1 year | -48.2% | -63.5% |
| Trend read | Strong downtrend | Strong downtrend |
| Analyst consensus | Buy | Buy |
Green cells mark the best value in each row where "better" is clear-cut (lower P/E, higher margin). That is a reading of the numbers, not a recommendation. Financials are in each company's reporting currency.
What the numbers say
- CORT is the largest of the group by market value.
- IBRX has returned the most over the past year.
- CORT is growing revenue fastest.
- CORT keeps the most profit per dollar of sales.
- CORT has been the calmest stock over the last 30 days.